News & Media

Jan 05, 2023

Arthrosi Announces Positive Topline Results For AR882 Phase 2B Study

Read More
Aug 23, 2022

Arthrosi Completes AR882 Phase 2b Study Enrollment

Read More
Aug 09, 2022

Arthrosi Completes AR882 Renal Impairment Study

Read More
Feb 22, 2022

Arthrosi Welcomes New Chief Financial Officer

Arthrosi announced the appointment of Philip Moody as its Chief Financial Officer, who brings more than 25 years of experience and a track record of success working in private and public biotech companies.

Read More
Dec 14, 2021

Arthrosi Therapeutics, Inc. Announces Patient Enrollment in Global Phase 2b Study of AR882

Arthrosi announced today patient enrollment in a global phase 2b study of AR882, its novel drug candidate. AR882 is a new uricosuric agent in clinical development for the management of hyperuricemia in patients with gout, including patients with chronic, refractory tophaceous gout.

Read More
Nov 02, 2021

Arthrosi Presents AR882 Posters at ACR 2021

Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced results from its renal impairment studies and human AME study.

Read More
Oct 12, 2021

Arthrosi Appoints Robert Thomas Keenan MD, MPH, MBA as Chief Medical Officer

Dr. Keenan has spent nearly 20 years in the field of rheumatology, bringing his vast expertise to the team as they reach Phase2b in the clinical development of the next generation molecule for the treatment of gout.

Read More
Aug 17, 2021

Arthrosi Establishes Joint Venture in China to Accelerate Development of Innovative Drug Portfolio

Arthrosi Therapeutics, Inc. today announced a joint venture in Guangzhou China with Ruiao Biopharmaceutical Technology Co., Ltd. ("a subsidiary of  ApicHope  Phamaceutical") to form Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

Read More
Jun 01, 2021

Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results

With AR882 showing strong efficacy and safety profile in Phase 2a study, Arthrosi is accelerating the development and looking to complete the Phase 2 studies by the middle of 2022.

Read More
May 10, 2021

Arthrosi’s New Molecule AR882 for Gout Shows Blockbuster-Potential

Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution. 

Read More